Table 4.

Effect of 2 months treatment with clopidogrel and with placebo on hepatic function markers (AST and ALT) in diabetic patients taking glibenclamide.

	Control (n = 16)	Clopidogrel group (n = 22)	Placebo group (n = 20)
AST (U/L)
Baseline	21.37 ± 1.32	22.73 ± 0.42a	22.7 ± 0.40a
After 60 days		23.23 ± 0.33⁎,b	22.75 ± 0.37a
% Change		2.2	0.22
ALT (U/L)
Baseline	17.813 ± 0.42	18.14 ± 0.43a	18.15 ± 0.30a
After 60 days		19.27 ± 0.40b	18.4 ± 0.36a
% Change		6.23	1.38

Data are expressed as mean ± SEM.

n = Number of subjects or patients.

Non-identical superscripts (a, b) within the same group represent significant difference (P < 0.05), by paired t-test.

^⁎P < 0.05 with respect to control group, by unpaired t-test.